Resmetirom

Introduction Resmetirom is a liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist used in the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. Its unique pharmacological profile allows for hepatic targeting to correct lipid metabolism abnormalities while avoiding systemic thyroid hormone-related side effects. Approved in 2024, resmetirom is a first-in-class therapeutic designed to … Read more